Could the split impact the company’s ability to raise capital in future financing rounds?

A 1‑for‑15 reverse split will lift Salarius’ share price roughly 15 times, moving the stock out of the “penny‑stock” range that many institutional investors and venture‑capital funds consider a red‑flag. By meeting Nasdaq’s minimum‑price requirement, the company preserves its listing on a more visible market tier, which can make future equity raises—whether through a public offering, a private placement, or a PIPE—logistically easier and more credible in the eyes of potential backers. Higher‑priced shares also reduce the dilution impact per dollar raised, allowing the firm to issue fewer shares to meet a given capital target, which is attractive when the company is still at a clinical‑stage, cash‑intensive phase.

However, the split does not automatically improve the firm’s capital‑raising fundamentals. The underlying balance sheet, cash‑burn rate, and the clinical‑trial pipeline still drive investor appetite. If the market perceives the reverse split as a cosmetic move to mask weakness, it could raise skepticism and lead to a higher discount on any new equity issuance. Moreover, the reduced float (15 times fewer shares) can thin liquidity, potentially widening bid‑ask spreads and making large secondary‑market purchases more costly for new investors. In practice, the split should be viewed as a prerequisite to keep the Nasdaq platform open and to present a more “institution‑friendly” price, but Salarius will still need to demonstrate solid clinical progress and a clear path to revenue to secure favorable financing terms.

Trading implication: Expect modest short‑term buying pressure as the split‑adjusted price clears the $5‑$10 threshold, but monitor volume and price stability. If the post‑split price holds and the company can deliver credible trial updates, the stock will be better positioned for a future equity raise at a lower discount; otherwise, the split alone will not offset weak fundamentals.